AstraZeneca has announced it will increase its full-year revenue and earnings forecast after exceeding analysts’ expectations in the second quarter.
The pharmaceutical giant reported a 18% surge in product sales, driven primarily by its oncology division. Key drugs like Imfinzi, Tagrisso, and Enhertu contributed significantly to the growth.
Despite a decline in core earnings per share compared to the previous year, which was influenced by one-off gains, the company’s overall financial performance was robust.
As a result of this strong performance, AstraZeneca has upwardly revised its full-year guidance, expecting both revenue and core earnings per share to grow by a mid-teen percentage.
To fuel future growth, the company has also increased its research and development spending and raised its interim dividend.
The positive results reflect AstraZeneca’s strong market position and its commitment to investing in innovative drug development.
Disclaimer:
This article is based on publicly available information and is intended for general informational purposes only. It does not constitute financial advice. Readers should conduct their own research or consult with a financial advisor before making any investment decisions.
The information presented here is believed to be accurate at the time of publication, but no warranty, express or implied, is made regarding its accuracy, completeness, or reliability.
